477584-42-2

Basic information

• Product Name: Carbamic acid, (tetrahydro-3-oxo-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (tetrahydro-3-oxo-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI)
• CAS NO: 477584-42-2
• Molecular Formula: C10H17NO4
• Molecular Weight: 215.24628
• Product Categories: N-BOC
• Mol File: 477584-42-2.mol

Chemical Properties

• Boiling Point: 351.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• PKA: 10.85±0.20(Predicted)
• CAS DataBase Reference: Carbamic acid, (tetrahydro-3-oxo-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (tetrahydro-3-oxo-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI)(477584-42-2)
• EPA Substance Registry System: Carbamic acid, (tetrahydro-3-oxo-2H-pyran-4-yl)-, 1,1-dimethylethyl ester (9CI)(477584-42-2)

Safety Data

• Hazardous Substances Data: 477584-42-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 445480-33-1 tert-butyl (trans-3-hydroxytetrahydro-2H-pyran-4-yl)carbamate 
• 1096770-58-9 (3R,4S)-4-aminotetrahydro-2H-pyran-3-ol 
• 445480-33-1 tert-butyl [(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]carbamate 

Relevant articles and documents

NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES

The present invention provides novel cyclic substituted imidazo[4,5- c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.